Citigroup Inc Protalix Bio Therapeutics, Inc. Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 24,756 shares of PLX stock, worth $54,215. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,756
Previous 2,292
980.1%
Holding current value
$54,215
Previous $5,000
620.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.84MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.54 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.36 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.81 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$1.1 Million0.01% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$1.09 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $109M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...